08:39 AM EDT, 09/23/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) and Sophia Genetics ( SOPH ) said Monday that they have partnered to develop a global liquid biopsy companion diagnostic test for pharmaceutical companies.

Under the partnership, the companies said they will leverage Myriad's advanced laboratory capabilities in the U.S. and Sophia Genetics' ( SOPH ) network of over 800 institutions in more than 70 countries for global test deployment.

The test, called MSK-ACCESS powered with Sophia DDM, analyzes tumor DNA from a blood sample and was co-developed with Memorial Sloan Kettering, the companies said.

They added that Myriad will handle regulatory submissions in the US, while Sophia Genetics ( SOPH ) will manage international approvals.